Tubular Reabsorption

Tubular reabsorption is the movement of substances from the lumen of the renal tubule, across the tubular epithelium, into the interstitial fluid, and finally into the peritubular capillaries. It is the second of the three basic renal processes — filtration, reabsorption, and secretion — and it is quantitatively the largest: of the ~180 L/day filtered at the glomerulus, about 178–179 L/day are reabsorbed, leaving only 1–2 L/day as final urine. Reabsorption can travel by two anatomically distinct routes. The transcellular route takes a solute or water molecule through the apical (luminal) membrane, across the cytoplasm, and out the basolateral membrane into the interstitium. This route requires the substance to cross two membranes and is where carrier proteins, channels, and pumps do their work. The paracellular route instead takes the substance between adjacent epithelial cells, through the tight junctions (zonulae occludentes) that join them. Paracellular transport is passive, driven by whatever concentration, electrical, or osmotic gradient exists across the epithelium, and its magnitude depends on how "leaky" or "tight" a particular tubule segment's junctions are. The proximal tubule has notably leaky junctions, permitting large paracellular fluxes of water and small ions, whereas the distal nephron has tighter junctions that allow steep gradients to be maintained. Underlying both routes is a single unifying principle: active transport of Na⁺, primarily by the Na⁺/K⁺-ATPase pump on the basolateral membrane, is the engine that drives nearly all other reabsorption, directly or indirectly. This pump hydrolyzes ATP to eject 3 Na⁺ from the cell into the interstitium in exchange for 2 K⁺ into the cell, keeping intracellular Na⁺ low (~10–15 mM versus ~140 mM in tubular fluid). This steep inward electrochemical gradient for Na⁺ is then harnessed by a family of apical membrane cotransporters and exchangers — secondary active transport — to pull glucose, amino acids, phosphate, and other solutes into the cell against their own gradients, "for free" in ATP terms, riding on the coattails of Na⁺'s downhill movement. Water follows osmotically, and many other ions follow via paracellular diffusion driven by the resulting electrochemical and osmotic gradients. This is why total body Na⁺ reabsorption is often called the master reabsorptive process of the nephron.

Step 1 — the Na⁺/K⁺-ATPase sets the gradient. In every reabsorptive tubule cell, the basolateral membrane is packed with Na⁺/K⁺-ATPase. It uses one ATP to pump 3 Na⁺ out and 2 K⁺ in per cycle, maintaining low intracellular Na⁺ and high intracellular K⁺. This single pump accounts for a large share of the kidney's total oxygen consumption — the kidneys make up about 0.5% of body mass but receive roughly 20–25% of cardiac output and consume a disproportionate share of resting O₂, largely to fuel this transport.

Step 2 — apical entry uses secondary active transport. Because intracellular Na⁺ is low, Na⁺ diffuses down its electrochemical gradient from the tubular lumen into the cell across the apical membrane. Various apical carrier proteins couple this favorable Na⁺ entry to the "uphill" entry of other solutes:

• SGLT2 (in the early proximal tubule, S1 segment) cotransports 1 Na⁺ : 1 glucose, handling roughly 90% of filtered glucose reabsorption.
• SGLT1 (later proximal tubule, S3 segment) cotransports 2 Na⁺ : 1 glucose with higher affinity, mopping up the remaining ~10%.
• Na⁺-amino acid cotransporters (several distinct systems for neutral, acidic, and basic amino acids) reabsorb amino acids by the same logic.
• The Na⁺/H⁺ exchanger (NHE3) drives H⁺ secretion into the lumen (important for HCO₃⁻ reabsorption and acid-base balance) while bringing Na⁺ into the cell.

Step 3 — basolateral exit. Once inside the cell, glucose and amino acids exit across the basolateral membrane by facilitated diffusion (e.g., GLUT2 transporters for glucose) down their concentration gradients into the interstitial fluid, from which they diffuse into peritubular capillaries. Na⁺ that entered apically is pumped out basolaterally by the Na⁺/K⁺-ATPase, completing the cycle.

Step 4 — water follows osmotically. As Na⁺, glucose, and other solutes accumulate in the lateral intercellular spaces between adjacent proximal tubule cells, local osmolality rises. Water follows by osmosis, both transcellularly through aquaporin-1 water channels (constitutively expressed and abundant in the proximal tubule) and paracellularly through the leaky tight junctions. This is the classical "solvent drag" and "standing osmotic gradient" model of proximal fluid reabsorption — water reabsorption here is obligatory and isosmotic, meaning the fluid leaving the proximal tubule has essentially the same osmolality as plasma (~300 mOsm/kg), even though about two-thirds of its volume is gone.

Step 5 — paracellular reabsorption of Cl⁻ and other ions. As Na⁺ and water are reabsorbed early in the proximal tubule, Cl⁻ concentration in the remaining lumen rises above its concentration in blood, because Cl⁻ is reabsorbed more slowly than Na⁺ initially (Na⁺ leaves paired with HCO₃⁻ and organic solutes preferentially). This Cl⁻ gradient then drives passive paracellular Cl⁻ reabsorption in the later proximal tubule, and a lumen-positive electrical gradient created by preferential Na⁺/HCO₃⁻ reabsorption is thought to help drive additional cation reabsorption paracellularly.

Step 6 — transport maximum (Tm) and threshold. Carrier-mediated transcellular transport systems like SGLT2 have a finite number of transporter molecules per unit tubule length. As the filtered load of a solute (filtered load = GFR × plasma concentration) rises, reabsorption rises proportionally — until the carriers are saturated. Beyond that point, called the transport maximum (Tm), any additional filtered solute cannot be reabsorbed and spills into the urine. For glucose, Tm averages about 375 mg/min in men (splay and nephron heterogeneity mean the measured curve bends gradually rather than sharply, a phenomenon called "splay"). The renal threshold, the plasma concentration at which glucose first appears in urine, is around 180–200 mg/dL — somewhat below the concentration predicted purely from Tm, because of this splay (nephron-to-nephron variability in Tm causes some nephrons to saturate before others).

The idea that the tubule actively reclaims specific solutes — rather than simply letting a passive filtrate pass through unchanged — required direct sampling of fluid at different points along single, living nephrons, since the composition changes drastically over microscopic distances that bulk urine analysis could never resolve.

Micropuncture (A. N. Richards and colleagues, 1920s–1940s). Working at the University of Pennsylvania, physiologist Alfred Newton Richards developed micropuncture: using fine glass micropipettes under a dissecting microscope, his team punctured individual renal tubules of anesthetized frogs and later mammals (Necturus, then rats) and withdrew nanoliter samples of tubular fluid at defined points along the nephron. By comparing the composition of fluid in Bowman's space (essentially a protein-free ultrafiltrate of plasma) to fluid sampled progressively further down the proximal tubule, Richards's group showed directly that:

• Glucose, present at plasma concentration in Bowman's capsule fluid, was essentially absent by the end of the proximal tubule — direct proof of near-complete glucose reabsorption.
• Fluid remained isosmotic to plasma along the proximal tubule even as its volume shrank, supporting the isosmotic bulk-reabsorption model.
• Inulin (a marker molecule that is filtered but neither reabsorbed nor secreted) became progressively more concentrated in tubular fluid as water was removed, allowing calculation of the fraction of filtered water reabsorbed at each point (the "tubular fluid/plasma inulin ratio" method, TF/P In).

This was direct, in vivo, segment-by-segment confirmation that filtration produces a fluid resembling plasma, and that the tubule then selectively removes glucose and water while inulin is left behind and concentrated — precisely because inulin is not reabsorbed. Richards received early recognition for essentially "watching" the kidney work in real time, transforming renal physiology from an inferential science based only on urine and blood analysis into a directly observational one.

Stop-flow analysis (Amos Malin, Robert Pitts, and colleagues, 1950s). A complementary technique, stop-flow, temporarily occluded the ureter, allowed tubular fluid to reach a steady distribution along the nephron, then released the clamp and collected sequential samples of the first urine to emerge — each aliquot corresponding roughly to fluid from a different tubular segment (proximal, loop, distal, collecting duct), reconstructed by comparison with a marker like creatinine or inulin whose concentration profile is known. Stop-flow experiments extended micropuncture's findings to segments (deep in the medulla) inaccessible to direct puncture and helped map where along the nephron different solutes (K⁺, phosphate, various ions) were reabsorbed or secreted.

Renal clearance and Tm determination (Homer Smith and colleagues, 1930s–40s). Using inulin clearance to measure GFR and simultaneous measurement of urinary and plasma glucose at rising plasma glucose concentrations (achieved by glucose infusion), researchers plotted filtered load, excretion rate, and calculated reabsorption rate against plasma glucose concentration. The resulting curve — reabsorption rate rising linearly then plateauing at a fixed maximum regardless of how much more glucose was filtered — was the first quantitative demonstration of a carrier-limited (saturable) transport process in the kidney, well before the SGLT transporter proteins themselves were cloned and characterized (SGLT1 and SGLT2 were identified molecularly only in the late 1980s–1990s). This established the Tm concept as an operational, measurable physiological ceiling decades before its molecular basis was known — a classic case of physiology outrunning molecular biology and later being vindicated by it. Together, these experiments established the core empirical facts that the mechanistic model above explains: segment-specific, saturable, energy-dependent reabsorption of specific solutes, isosmotic bulk fluid reabsorption in the proximal tubule, and a hard transport ceiling that produces glucosuria once exceeded.

Example 1 — Calculating filtered load, Tm, and predicting glucosuria. A patient has:

• GFR = 125 mL/min
• Plasma glucose = 300 mg/dL
• Renal Tm for glucose = 375 mg/min

Step 1: Convert plasma glucose to mg/mL: 300 mg/dL = 3.0 mg/mL. Step 2: Filtered load = GFR × plasma concentration = 125 mL/min × 3.0 mg/mL = 375 mg/min. Step 3: Compare to Tm (375 mg/min). Filtered load ≈ Tm, so the patient is right at the saturation point — reabsorption is nearly maximal, and a small amount of glucose likely just begins to appear in urine (accounting for splay, some nephrons saturate slightly before this point). Now suppose plasma glucose rises further to 400 mg/dL (severe hyperglycemia, as in poorly controlled diabetes mellitus): Filtered load = 125 mL/min × 4.0 mg/mL = 500 mg/min. Reabsorption is capped at Tm = 375 mg/min (assuming no further increase is possible). Excretion rate = filtered load − reabsorption rate = 500 − 375 = 125 mg/min of glucose lost in urine. This directly demonstrates why uncontrolled diabetes produces glucosuria and, via the osmotic pull of unreabsorbed glucose retaining water in the tubule, why diabetic patients experience polyuria and thirst (osmotic diuresis) — a direct clinical consequence of exceeding Tm. It also explains the pharmacological logic of SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin): by blocking the SGLT2 carrier in the early proximal tubule, these drugs deliberately lower the effective Tm for glucose, causing glucose to be excreted at lower plasma concentrations — used therapeutically to lower blood glucose in type 2 diabetes (and shown, in later cardiovascular/renal outcome trials, to reduce heart failure hospitalization and slow kidney disease progression, benefits partly independent of glycemic control).

Example 2 — Proximal tubule bulk reabsorption and downstream nephron load. Suppose GFR = 180 L/day and the proximal tubule reabsorbs 65% of filtered Na⁺ and water isosmotically. Filtered Na⁺ load, taking plasma Na⁺ as 140 mEq/L: Filtered Na⁺ = 180 L/day × 140 mEq/L = 25,200 mEq/day. Proximal tubule reabsorption (65%): 25,200 × 0.65 = 16,380 mEq/day reabsorbed proximally. Remaining Na⁺ entering the loop of Henle: 25,200 − 16,380 = 8,820 mEq/day (35% of filtered load). Correspondingly, of the 180 L/day filtered water, 65% (117 L/day) is reabsorbed proximally, leaving 63 L/day to enter the loop of Henle. This calculation illustrates a crucial physiological point that anticipates the countercurrent system: the proximal tubule performs bulk, unregulated (or only loosely regulated), isosmotic reabsorption — it is not the site of fine hormonal control. The remaining 35% of the filtered Na⁺ and water load is then handled by downstream segments (loop of Henle, distal tubule, collecting duct), where finely tuned, hormonally regulated reabsorption (aldosterone acting on principal cells, ADH controlling water permeability via aquaporin-2 insertion) determines the final, small volume and precise composition of urine — typically only 1–2 L/day and under 1% of filtered Na⁺. This division of labor — "coarse" bulk reabsorption proximally, "fine-tuning" distally — is a recurring organizational theme in renal physiology.

Richards trained originally in pharmacology and turned to kidney physiology relatively late in his career, but his meticulous, technically difficult micropuncture experiments — first performed on the amphibian Necturus (mudpuppy), whose enormous glomeruli and tubules made puncture technically feasible, and later extended to mammals — became foundational. He served as a professor and later vice-president for medical affairs at the University of Pennsylvania, and during World War II he also chaired the U.S. Committee on Medical Research, overseeing wartime development of penicillin production and other medical advances — a reminder that many classic physiologists moved fluidly between basic science and applied, high-stakes research.

Diabetes management and SGLT2 inhibitors. Drugs such as empagliflozin, canagliflozin, and dapagliflozin block SGLT2 in the proximal tubule, deliberately lowering the effective renal glucose threshold so that excess glucose is excreted rather than reabsorbed. Large clinical trials (e.g., EMPA-REG OUTCOME, DAPA-HF) found these drugs reduce cardiovascular death and heart failure hospitalization and slow progression of chronic kidney disease, effects now understood to extend well beyond simple glucose lowering, likely involving reduced proximal tubule workload and altered tubuloglomerular feedback.

Diuretic pharmacology. Because different nephron segments use different specific transporters, drugs can be targeted with segment-specific precision: loop diuretics (furosemide) block the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb; thiazides block the Na⁺-Cl⁻ cotransporter in the distal convoluted tubule; potassium-sparing diuretics (amiloride, spironolactone) act on the collecting duct's ENaC channel or aldosterone receptor. Understanding segmental reabsorption mechanisms directly explains each drug's site of action, potency, and side-effect profile (e.g., loop diuretics cause more severe K⁺ and Ca²⁺ wasting because they disrupt the largest fraction of filtered Na⁺ reabsorption).

Renal glucosuria and genetic transporter disorders. Mutations in SGLT2 (familial renal glucosuria) or in amino acid transporters (e.g., cystinuria, caused by defective cystine/dibasic amino acid transporters) directly demonstrate the clinical consequences of losing specific reabsorptive carriers, producing selective solute loss in urine despite normal plasma levels and normal GFR.

Fluid and electrolyte therapy in critical care. Understanding how much filtered Na⁺ and water are reabsorbed at each segment underlies rational use of IV fluids, diuretics, and monitoring of urine output and electrolytes in patients with acute kidney injury, heart failure, or cirrhosis, where reabsorptive capacity is altered by disease or drugs.

Toxicology and drug design. Because many drugs and toxins are handled by the same transporters used for normal solute reabsorption (or by parallel secretory transporters), pharmacologists exploit or must account for tubular reabsorption when designing drugs intended to be excreted efficiently versus retained.

Ask the tutor: How does selective reabsorption in the loop of Henle set up the countercurrent multiplier system that concentrates urine?